BGN-112

BGN-112 is a novel first-in-class drug candidate composed of proprietary biocompatible GQDs
Among the varying types of soluble graphene-based nanomaterials, Graphene Quantum Dots (GQDs) display some of the most promising properties in terms of biocompatibility. Nanometer-sized graphene quantum dots are known to exhibit negligible toxicity with excellent stability in physiological conditions, attracting attention as bioimaging, diagnostic agents, and drug delivery platforms. Their amphiphilic properties are advantageous in interfering with or breaking down the formation of undesirable aggregations (i.e. neuroproteins/cholesterol) in the body. With years of experience and acquired expertise, BioGraphene has developed its new drug candidate, BGN-112, as a potential treatment for indications such as Parkinson’s, Alzheimer’s, and Niemann-Pick disease Type C (NPC) as well as ALS and others.